Published in Vaccine Weekly, March 30th, 2005
Tibotec presented interim phase IIb results on TMC114, a protease inhibitor (PI) studied in heavily treatment-experienced patients. Tibotec also presented the first clinical results of a new non-nucleoside reverse transcriptase inhibitor, TMC278; and data on a novel class of nucleotide-competitive reverse transcriptase inhibitors.
The company is also developing a compound for tuberculosis, an important...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly